# US 2003/0211467 A1 · Methods and compositions for detecting hepatitis E virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211467 A1
- Document ID: US20030211467A1
- Status: Published application
- Kind: A1
- Application number: 10/319,745
- Filed: 2002-12-13
- Published: 2003-11-13
- Earliest claimed: 1999-12-21
- Inventors: George G. Schlauder; James C. Erker; Suresh M. Desai; George J. Dawson; Isa K. Mushahwar
- Web page: https://patentgrep.com/patent/US20030211467A1

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- G01N 33/5767: {non-A, non-B hepatitis}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2770/28122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are methods and compositions for detecting the presence in a sample of a US-type or a US-subtype hepatitis E virus, including naturally occurring variants thereof. In particular, the invention provides nucleic acid sequences corresponding to the genome of the US-type or US-subtype hepatitis E virus, amino acid sequences, including epitope sequences, encoded by the genomes of such viruses, and antibodies that bind specifically to such amino acid sequences. The invention further provides methods and compositions for immunizing individuals against infection by, or for treating individuals already infected with such a virus.

## Claims

### Claim 1

A method of detecting the presence of a US-type or US-subtype hepatitis E virus (HEV) or a naturally occurring variant thereof in a test sample, the method comprising the steps of:
(a) contacting the sample with a binding partner that binds specifically to a marker for said virus, which if present in the sample binds to the binding partner to produce a marker-binding partner complex, and
(b) detecting the presence of said complex, the presence of said complex being indicative of the presence of said virus in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein said marker is an antibody capable of binding said virus.

### Claim 3 (depends on 2)

The method of claim 2, wherein said antibody is an immunoglobulin G or an immunoglobulin M.

### Claim 4 (depends on 2)

The method of claim 2, wherein said binding partner is an isolated polypeptide chain.

### Claim 5 (depends on 4)

The method of claim 4, wherein said polypeptide chain is immobilized on a solid support.

### Claim 6 (depends on 4)

The method of claim 4, wherein said binding partner is a polypeptide chain selected from the group consisting of SEQ ID NOS: 91, 92, and 93, including naturally occurring variants thereof.

### Claim 7 (depends on 4)

The method of claim 4, wherein said binding partner is a polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 173 or SEQ ID NO: 175.

### Claim 8 (depends on 4)

The method of claim 4, where said binding partner is a polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 174 or SEQ ID NO: 176.

### Claim 9 (depends on 4)

The method of claim 4, wherein said binding partner is a polypeptide chain selected from the group consisting of SEQ ID NOS: 166, 167 and 168, including naturally occurring variants thereof.

### Claim 10 (depends on 4)

The method of claim 4, wherein said binding partner is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 223.

### Claim 11 (depends on 4)

The method of claim 4, wherein said binding partner is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 224.

### Claim 12 (depends on 1)

The method of claim 1, wherein said binding partner is an isolated antibody capable of binding specifically to a polypeptide chain selected from the group consisting of SEQ ID NOS: 91, 92, 93, 166, 167, and 168, including naturally occurring variants thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein said antibody is a monoclonal antibody.

### Claim 14 (depends on 1)

The method of claim 1, wherein said marker is a polypeptide chain.

### Claim 15 (depends on 14)

The method of claim 14, wherein said polypeptide chain is selected from the group consisting of SEQ ID NOS: 91, 92, and 93, including naturally occurring variants thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein said polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 173 or SEQ ID NO: 175.

### Claim 17 (depends on 14)

The method of claim 14, wherein said polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 174 or SEQ ID NO: 176.

### Claim 18 (depends on 14)

The method of claim 14, wherein said polypeptide chain is selected from the group consisting of SEQ ID NOS: 166, 167, and 168, including naturally occurring variants thereof.

### Claim 19 (depends on 14)

The method of claim 14, wherein said polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 223.

### Claim 20 (depends on 14)

The method of claim 14, wherein said polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 224.

### Claim 21 (depends on 1)

The method of claim 1, wherein said marker is a nucleic acid sequence defining at least a portion of a genome of said virus, or a complementary strand thereof.

### Claim 22 (depends on 1)

The method of claim 1 wherein said binding partner is an isolated nucleic acid sequence that is capable of hybridizing under specific hybridization conditions to the nucleic acid sequences set forth in SEQ ID NOS: 89 and 164.

### Claim 23 (depends on 1)

The method of claim 1 wherein said binding partner is selected from the group consisting of SEQ ID NOS: 126, 128, 147, 148, 150, 152, 177, 178, 255, 256, 257, and 258.

### Claim 24 (depends on 1)

The method of claim 1 wherein said binding partner is an isolated polypeptide chain.

### Claim 25 (depends on 1)

The method of claim 1 wherein said test sample is a mammalian cell line.

### Claim 26 (depends on 41)

The method of claim 41 wherein said mammalian cell line is a human fetal kidney cell line.

### Claim 27

A method of detecting the presence of a hepatitis E virus (HEV) in a test sample, the method comprising the steps of:
(a) contacting the sample with a binding partner selected from the group consisting of SEQ ID NOS: 126, 128, 147, 148, 150, 152, 177, 178, 255, 256, 257, and 258 that binds specifically to a marker for said virus, which if present in the sample binds to the binding partner to produce a marker-binding partner complex, and
(b) detecting the presence of said complex, the presence of said complex being indicative of the presence of said virus in the sample.

### Claim 28

An isolated polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 223 and SEQ ID NO: 224.

### Claim 29

An isolated antibody capable of binding specifically to a polypeptide chain selected from the group consisting of a polypeptide encoded by an ORF 1 sequence of a US-type or a US-subtype HEV, a polypeptide encoded by an ORF 2 sequence of a US-type or a US-subtype HEV, and a polypeptide encoded by an ORF 3 sequence of a US-type or a US-subtype HEV.

### Claim 30

An isolated antibody capable of binding specifically to a polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 173, SEQ ID NO: 175 or SEQ ID NO: 224.

### Claim 31

An isolated antibody capable of binding specifically to a polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 174, SEQ ID NO: 176 or SEQ ID NO: 223.

### Claim 32 (depends on 30)

The isolated antibody of claim 30, wherein said antibody, under similar conditions, has a lower affinity for a polypeptide chain comprising the amino acid sequence set forth in SEQ ID NO: 169 or 171.

### Claim 33 (depends on 31)

The isolated antibody of claim 31, wherein said antibody, under similar conditions, has a lower affinity for a polypeptide chain comprising the amino acid sequence set forth SEQ ID NO: 170 or 172.

### Claim 34 (depends on 29)

The isolated antibody of claim 29 further comprising a detectable moiety.

### Claim 35

An isolated nucleic acid sequence defining at least a portion of an ORF 1, ORF 2 or ORF 3 sequence of a US-type or US-subtype hepatitis E virus, or a sequence complementary thereto.

### Claim 36

An isolated nucleic acid sequence capable of hybridizing under specific hybridization conditions to the nucleotide sequence set forth in SEQ ID NOS: 89 and 164.

### Claim 37 (depends on 35)

A vector comprising the isolated nucleic acid sequence of claim 35.

### Claim 38 (depends on 37)

A host cell containing the vector of claim 37.

### Claim 39 (depends on 28)

A method of immunizing a mammal against a US-type or US-subtype HEV, the method comprising administering to the mammal the polypeptide of claim 28 in an amount sufficient to stimulate the production of an antibody capable of binding specifically to the US-type or US-subtype hepatitis E virus.

### Claim 40 (depends on 29)

A method of immunizing a mammal against a US-type or US-subtype HEV 1, the method comprising administering to said mammal the antibody of claim 29 in an amount sufficient to immunize said mammal against the US-type or US-subtype hepatitis E virus.

### Claim 41 (depends on 30)

A method of immunizing a mammal against a US-type or US-subtype HEV 1, the method comprising administering to said mammal the antibody of claim 30 in an amount sufficient to immunize said mammal against the US-type or US-subtype hepatitis E virus.

### Claim 42 (depends on 31)

A method of immunizing a mammal against a US-type or US-subtype HEV 1, the method comprising administering to said mammal the antibody of claim 31 in an amount sufficient to immunize said mammal against the US-type or US-subtype hepatitis E virus.

### Claim 43 (depends on 38)

A method of immunizing a mammal against a US-type or US-subtype HEV, the method comprising administering to said mammal the host cell of claim 38 in an amount sufficient to immunize said mammal against the US-type or US-subtype hepatitis E virus.
